Search Within

David Nemirovsky

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (12)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (40)
  2. Epidemiology and Biostatistics (40)
  3. Department of Medicine (37)
  4. Graduate Medical Education (31)
  5. Center for Hematologic Malignancies (30)
  6. Hematologic Malignancies, Division of (30)

More Groups

People
  1. Andriy Derkach (27)
  2. Sergio Giralt (21)
  3. Alexander Lesokhin (20)
  4. Carlyn Rose Tan (20)
  5. David Chung (20)
  6. Gunjan Shah (20)

More People

Years
  1. 2025 (2)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (2)
Publications
  1. Blood (15)
  2. Clinical Lymphoma, Myeloma and Leukemia (7)
  3. Blood Advances (3)
  4. Blood Cancer Journal (3)
  5. Journal of Clinical Oncology (3)
  6. Transplantation and Cellular Therapy (3)

More Publications

Publishers
  1. American Society of Hematology (18)
  2. Elsevier Inc. (10)
  3. American Society of Clinical Oncology (3)
  4. Nature Publishing Group (3)
  5. Oxford University Press (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Precision lineage deconvolution in mixed phenotype acute leukemia using CITE-seq derived hematopoietic stages identifies lineage dynamics associated with treatment response
    Meeting Abstract

    Dilip, D.; Galera, P.; Nemirovsky, D.; Lallo, M.; Menghrajani, K.; Derkach, A.; Levine, R. L.; Koche, R.; Xiao, W.; Glass, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Prognostic implications of HER2 gain in patients with HR+/ HER2-breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Ferraro, E.; Chew Minmin, S.; Nemirovsky, D.; Chen, Y.; Barrio, A. V.; Modi, S.; Seidman, A.; Wen, H.; Brogi, E.; Robson, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save